Study of Peptide Vaccine in Treating Patients with Newly Diagnosed Plasma Cell LeukemiaResearch Question:
What is the safety of a peptide vaccine (called SVN53-67/M57-KLH) in treating patients
with newly diagnosed multiple myeloma (plasma cell leukemia) who are receiving chemotherapy?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This study looks at treating patients with newly diagnosed multiple myeloma (plasma
cell leukemia) who are receiving lenalidomide maintenance therapy, a kind of maintenance
chemotherapy. Specifically, this study will look at the safety of SVN53-67/M57-KLH
peptide vaccine in incomplete Freund's adjuvant together with sargramostim. This
peptide vaccine may help the body build an effective immune response to kill certain
cancer cells. Incomplete Freund's adjuvant may help stimulate the body's immune response
to the vaccine treatment. Sargramosti may increase the production of blood cells.
Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth. Giving SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant
and sargramostim before or after the start of lenalidomide maintenance therapy may
be a better treatment for multiple myeloma.
Study Reference #: UMMY18067
Lead Researcher (Principal Investigator)
Lead Researcher: Brea Lipe
Study Contact InformationStudy Coordinator: Stephanie Short
Phone: (585) 276-7885
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search